Psividacor Cdi News - PVA

pSivida Corp. Reports Third Quarter FY 2015 Results

Clear FDA Regulatory Path for Medidur™ for Posterior Uveitis NDA Filing Planned in First Half of 2017 pSivida Corp. (NASDAQ:PSDV...

pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Corp. Reports ILUVIEN® for DME Approved in Poland

Marks 17th European Approval pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products...

pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23

Live Launch Webinar on March 2 pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery...

pSivida Corp. Reports Second Quarter FY 2015 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases...

pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Reports Commencement of ILUVIEN® Sales in Portugal

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands

Now Approved in 14 Countries Worldwide pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug...

pSivida CEO to Present at LD Micro Investor Conference

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Reports ILUVIEN® Granted Marketing Authorization in Ireland

Now Approved in 13 Countries Worldwide pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug...

pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium

Now Approved in 12 Countries Worldwide pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug...

pSivida Corp. Reports First Quarter FY 2015 Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Psividacor Cdi (PVA)

Professional-Grade Tools, for Individual Investors.

PVA News

pSivida Corp. Reports Third Quarter FY 2015 Results

pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Corp. Reports ILUVIEN® for DME Approved in Poland

pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23

pSivida Corp. Reports Second Quarter FY 2015 Results

pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9

pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries

pSivida Reports Commencement of ILUVIEN® Sales in Portugal

pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands

pSivida CEO to Present at LD Micro Investor Conference

pSivida Reports ILUVIEN® Granted Marketing Authorization in Ireland

pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium

pSivida Corp. Reports First Quarter FY 2015 Results

PVA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Psividacor Cdi (PVA) News

Psividacor Cdi (PVA)

Professional-Grade Tools, for Individual Investors.

PVA News

pSivida Corp. Reports Third Quarter FY 2015 Results

pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Corp. Reports ILUVIEN® for DME Approved in Poland

pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23

pSivida Corp. Reports Second Quarter FY 2015 Results

pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9

pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries

pSivida Reports Commencement of ILUVIEN® Sales in Portugal

pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands

pSivida CEO to Present at LD Micro Investor Conference

pSivida Reports ILUVIEN® Granted Marketing Authorization in Ireland

pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium

pSivida Corp. Reports First Quarter FY 2015 Results

PVA Discussion

Your Recent History